Evaluation of efficacy and safety for recombinant human adenovirus-p53 in the control of the malignant pleural effusions via thoracic perfusion

Evaluation of efficacy and safety for recombinant human adenovirus-p53 in the control of the malignant pleural effusions via thoracic perfusion

A certain number of studies have showed that p53 gene transfer has an anti-tumor activity in vitro and in vivo . This study was to evaluate the efficacy and safety of thoracic perfusion of recombinant human adenovirus p53 (rAd-p53, Gendicine) for controlling malignant pleural effusion (MPE). We sear...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports 2016-12, Vol.6 (1), p.39355-39355, Article 39355
Hauptverfasser: Biaoxue, Rong, Hui, Pan, Wenlong, Gao, Shuanying, Yang
Format: Artikel
Sprache:eng
Schlagworte:
631/67/1612/1350
692/4028/67/1059/602
Adenoviruses
Antitumor agents
Chemotherapy
Clinical trials
Disease control
Fever
Gene transfer
Humanities and Social Sciences
multidisciplinary
p53 Protein
Perfusion
Pleural effusion
Quality of life
Safety
Science
Side effects
Thorax
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A certain number of studies have showed that p53 gene transfer has an anti-tumor activity in vitro and in vivo . This study was to evaluate the efficacy and safety of thoracic perfusion of recombinant human adenovirus p53 (rAd-p53, Gendicine) for controlling malignant pleural effusion (MPE). We searched for the relevant studies from the database of MEDLINE, Web of Science, EMBASE, Cochrance Library and CNKI to collect the trials concerning the efficacy and safety of rAd-p53 to treat MPE. Fourteen randomised controlled trials (RCTs) with 879 patients were involved in this analysis. The rAd-p53 combined with chemotherapeutic agents significantly improved the overall response rate (ORR) (P 
ISSN:2045-2322
2045-2322
DOI:10.1038/srep39355